Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Long-Term Debt: ¥2,134 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605077 Zhejiang Huakang Pharmaceutical Co Ltd SHSE:605077
73 GF Score
Price ¥10.78
GF Value ¥30.12
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zhejiang Huakang Pharmaceutical Co Long-Term Debt?

Zhejiang Huakang Pharmaceutical Co SHSE:605077 -2.27% 73 Long-Term Debt is ¥2,134 Mil as of Jun. 2026. GuruFocus rates SHSE:605077 with a GF Score™ of 73/100 and a GF Value™ of ¥30.12 (Possible Value Trap). The stock has 7 warning signs investors should review.

Zhejiang Huakang Pharmaceutical Co's Long-Term Debt for the quarter that ended in Jun. 2026 was ¥2,134 Mil.

Zhejiang Huakang Pharmaceutical Co's quarterly Long-Term Debt declined from Dec. 2025 (¥2,110 Mil) to Mar. 2026 (¥2,052 Mil) but then increased from Mar. 2026 (¥2,052 Mil) to Jun. 2026 (¥2,134 Mil).

Zhejiang Huakang Pharmaceutical Co's annual Long-Term Debt declined from Dec. 2023 (¥1,868 Mil) to Dec. 2024 (¥1,859 Mil) but then increased from Dec. 2024 (¥1,859 Mil) to Dec. 2025 (¥2,110 Mil).

Zhejiang Huakang Pharmaceutical Co  (SHSE:605077) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Zhejiang Huakang Pharmaceutical Co Long-Term Debt Related Terms

Zhejiang Huakang Pharmaceutical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Zhejiang Huakang Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Huakang Pharmaceutical Co Long-Term Debt Chart

Zhejiang Huakang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.02 345.46 1,868.48 1,859.46 2,110.02

Zhejiang Huakang Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,220.28 2,188.11 2,110.02 2,051.99 2,133.67
SHSE:605077
73GF Score
Zhejiang Huakang Pharmaceutical Co Ltd SHSE:605077
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥2,134 Mil mean?
Zhejiang Huakang Pharmaceutical Co (SHSE:605077) has a Long-Term Debt of ¥2,134 Mil as of Jun. 2026.
Is Zhejiang Huakang Pharmaceutical Co's Long-Term Debt too high?
Zhejiang Huakang Pharmaceutical Co's current Long-Term Debt is ¥2,134 Mil. Overall, Zhejiang Huakang Pharmaceutical Co has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Huakang Pharmaceutical Co's Long-Term Debt compare to DOW?
Zhejiang Huakang Pharmaceutical Co's Long-Term Debt of ¥2,134 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Chemicals company?
A good Long-Term Debt depends on the Chemicals industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Zhejiang Huakang Pharmaceutical Co's current Long-Term Debt is ¥2,134 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Huakang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Huakang Pharmaceutical Co (SHSE:605077) is currently considered Possible Value Trap. The stock's GF Value™ is ¥30.12, compared to a current price of ¥10.78 — trading 64.2% below its estimated fair value. The current Long-Term Debt is ¥2,134 Mil. Zhejiang Huakang Pharmaceutical Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Zhejiang Huakang Pharmaceutical Co (SHSE:605077), the current Long-Term Debt is ¥2,134 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Huakang Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥10.78 is trading 64.2% below its estimated GF Value™ of ¥30.12. GuruFocus considers Zhejiang Huakang Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:605077:

  • Long-Term Debt: ¥2,134 Mil
  • GF Value™: ¥30.12 vs. price of ¥10.78 (64.2% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the SHSE:605077 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Huakang Pharmaceutical Co Business Description

Address No. 18, Huagong Road, Huabu Town, Zhejiang Province, Kaihua County, Quzhou, CHN, 324302
Zhejiang Huakang Pharmaceutical Co Ltd is engaged in the research and development, production and sales of various functional sugar alcohols and starch sugar products such as xylitol, sorbitol, maltitol, fructose syrup and others.
73GF Score

Get the complete analysis for SHSE:605077

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.78
Price
¥30.12
GF Value